EVENITY® (Amgen Inc)
(https://evenity.com) 📸 Data Snapshot: May 30, 2026Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
The authority is well-established through Amgen’s Organization schema, but there is an expert footprint gap. Testimonials like the quote about completing the 12-month protocol are attributed to individuals without a verifiable digital footprint or Person schema. Technical implementation is strong, with proper Drug and MedicalWebPage schema, though the lack of sameAs links for the ‘Call center representative’ or specific clinical leads creates a minor authority gap in the expertise properties.
The marketing tone is highly optimistic (‘results were astounding’), which creates a minor disconnect with the severe clinical warnings required by the FDA. While the site claims a ‘proven’ track record, it does not demonstrate the specific percentage of risk reduction directly in the H2s or H3s, opting for the vague ‘significantly reduce’ rather than raw data points in the top-level hierarchy. This reliance on the prescribing information PDF to hold all substance while the UI presents marketing summaries is a standard pharma disconnect.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
[
{
"@context": "https://schema.org",
"@type": "WebSite",
"url": "https://www.evenity.com/",
"name": "EVENITY®",
"publisher": {
"@type": "Organization",
"name": "Amgen Inc"
}
},
{
"@context": "https://schema.org",
"@type": "Drug",
"isProprietary": true,
"name": "EVENITY® (romosozumab_aqqg)",
"activeIngredient": "romosozumab_aqqg",
"administrationRoute": "injection",
"dosageForm": "injection",
"prescriptionStatus": "PrescriptionOnly",
"drugClass": {
"@type": "DrugClass",
"name": "sclerostin inhibitor"
},
"relatedDrug": {
"@type": "Drug",
"name": "Prolia"
},
"manufacturer": {
"@type": "Organization",
"name": "Amgen Inc"
}
}
]
/about-evenity/how-evenity-works/
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"medicalAudience": "Patient",
"specialty": "Rheumatology",
"url": "https://www.evenity.com/about-evenity",
"headline": "EVENITY® (romosozumab_aqqg) Patient Home Page",
"description": "Learn more about EVENITY®, a treatment for women with postmenopausal osteoporosis. See Full Prescribing & Safety info.",
"primaryImageOfPage": "https://www.evenity.com/-/media/Themes/Amgen/Evenity-com/Evenity-com/images/Redesign/Icons/how-evenity-works.png",
"mainContentOfPage": {
"@type": "WebPageElement",
"name": "EVENITY is a one-of-a-kind osteoporosis treatment—the first and only one that works both ways by building new bone and helping to slow bone loss."
},
"about": [
{
"@type": "MedicalProcedure",
"name": "EVENITY® (romosozumab_aqqg)",
"procedureType": "Subcutaneous",
"howPerformed": "Injection"
}
]
},
{
"@context": "https://schema.org",
"@type": "Drug",
"isProprietary": true,
"name": "EVENITY® (romosozumab_aqqg)",
"activeIngredient": "romosozumab_aqqg",
"administrationRoute": "subcutaneous",
"dosageForm": "injection",
"drugClass": "sclerostin inhibitor",
"manufacturer": {
"@type": "Organization",
"name": "Amgen Inc"
}
},
{
"@context": "https://schema.org",
"@type": "VideoObject",
"name": "Watch How Evenity Works",
"description": "How Evenity works by increasing the activity of bone-building cells and slowing down bone loss by decreasing your body's bone-removing activity",
"thumbnailUrl": "https://house-fastly-signed-eu-west-1-prod.brightcovecdn.com/image/v1/static/6415657469001/32875482-8e5b-4d9d-bd53-771f34bb934a/7d1f6a49-8d04-45c4-82a9-b241a1b3bfc8/1280x720/match/image.jpg",
"uploadDate": "2025-01-01T08:00:00+08:00",
"duration": "PT5M35S"
}
]
/contact-us/
{
"@context": "https://schema.org",
"@type": "ContactPage",
"mainEntity": {
"@type": "ContactPoint",
"telephone": "+1-888-231-5663",
"contactType": "call center representative",
"areaServed": "US",
"productSupported": "Evenity",
"availableLanguage": "en"
}
}
/results-and-safety/clinical-trial-results/
[
{
"@context": "https://schema.org",
"@type": "MedicalWebPage",
"medicalAudience": "Patient",
"specialty": "Rheumatology",
"url": "https://www.evenity.com/results-and-safety/clinical-trial-results",
"headline": "EVENITY® is proven to significantly reduce spine fracture risk",
"description": "See EVENITY® clinical trial information and learn how it can help women with postmenopausal osteoporosis at a high risk for fracture. See Full Prescribing & Safety Info.",
"primaryImageOfPage": "https://www.evenity.com/results-and-safety/-/media/Themes/Amgen/Evenity-com/Evenity-com/images/Redesign/Desktop/proven-results/BMD.png",
"mainContentOfPage": {
"@type": "WebPageElement",
"name": "EVENITY is proven to significantly increase bone MINERAL density in the lumbar spine, total hip, and femoral neck"
}
},
{
"@context": "https://schema.org",
"@type": "MedicalTrial",
"name": "EVENITY Clinical Trials",
"description": "EVENITY is proven to significantly increase bone MINERAL density in the lumbar spine, total hip, and femoral neck",
"studySubject": {
"@type": "MedicalEntity",
"name": "women with postmenopausal osteoporosis"
}
}
]
🛡️ Trust Signals — external proof links that back the declared identity
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 2 | 0 |
| /about-evenity/how-evenity-works/ | 2 | 0 |
| /contact-us/ | 2 | 0 |
| /results-and-safety/clinical-trial-results/ | 3 | 0 |
This page presents a snapshot of public data from EVENITY® (Amgen Inc), captured on May 30, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to EVENITY® (Amgen Inc): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://evenity.com to view the most current version of its content and see directly what this company is about and what it offers.